Literature DB >> 18413332

Fluvastatin treatment and withdrawal: effects on endothelial function.

Sabine Westphal1, Claudia Abletshauser, Claus Luley.   

Abstract

Fluvastatin lowers lipids and protects endothelial function. This study investigated how 2 preparations of fluvastatin would affect endothelial function after treatment and early after its discontinuation. Twenty-seven patients received 80 mg extended-release fluvastatin every day, 40 mg immediate-release fluvastatin twice a day, or placebo for 5 weeks. Fasting lipids and flow-mediated dilation were measured at baseline and after each treatment period. In 21 patients, flow-mediated vasodilation was also measured 24 hours after discontinuation of therapy. Both forms of fluvastatin improved flow-mediated vasodilation (extended release: P < .037 and immediate release: P < .001). However, this improvement occurred preferentially in patients with low baseline flow-mediated vasodilation (<5%). Twenty-four hours after treatment discontinuation, the flow-mediated vasodilation deteriorated again to baseline (extended release and immediate release: P < .001). Fluvastatin improved flow-mediated vasodilation only in patients with low baseline values. Twenty-four hours after discontinuation, the flow-mediated vasodilation deteriorated again, surprisingly irrespective of prior improvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413332     DOI: 10.1177/0003319708316005

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

Review 1.  Statin rebound or withdrawal syndrome: does it exist?

Authors:  Andres Pineda; Luigi X Cubeddu
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

2.  Low fingertip temperature rebound measured by digital thermal monitoring strongly correlates with the presence and extent of coronary artery disease diagnosed by 64-slice multi-detector computed tomography.

Authors:  Naser Ahmadi; Vahid Nabavi; Vivek Nuguri; Fereshteh Hajsadeghi; Ferdinand Flores; Mohammad Akhtar; Stanley Kleis; Harvey Hecht; Morteza Naghavi; Matthew Budoff
Journal:  Int J Cardiovasc Imaging       Date:  2009-07-26       Impact factor: 2.357

3.  Association of coronary artery calcium score and vascular dysfunction in long-term hemodialysis patients.

Authors:  Irfan Zeb; Naser Ahmadi; Miklos Z Molnar; Dong Li; Ronney Shantouf; Parta Hatamizadeh; Taeyoung Choi; Kamyar Kalantar-Zadeh; Matthew J Budoff
Journal:  Hemodial Int       Date:  2012-09-11       Impact factor: 1.812

4.  Preinjury statin use is associated with a higher risk of multiple organ failure after injury: a propensity score adjusted analysis.

Authors:  Matthew D Neal; Joseph Cushieri; Matthew R Rosengart; Louis H Alarcon; Ernest E Moore; Ronald V Maier; Joseph P Minei; Timothy R Billiar; Andrew B Peitzman; Jason L Sperry
Journal:  J Trauma       Date:  2009-09

Review 5.  Fluvastatin for lowering lipids.

Authors:  Stephen P Adams; Sarpreet S Sekhon; Michael Tsang; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2018-03-06

6.  Impact of Increased Early Statin Administration on Ischemic Stroke Outcomes: A Multicenter Electronic Medical Record Intervention.

Authors:  Alexander C Flint; Carol Conell; Jeff G Klingman; Vivek A Rao; Sheila L Chan; Hooman Kamel; Sean P Cullen; Bonnie S Faigeles; Steve Sidney; S Claiborne Johnston
Journal:  J Am Heart Assoc       Date:  2016-07-29       Impact factor: 5.501

7.  Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Chung-Yu Chen; Wen-Ting Wu; Ya-Ling Wang; Kuang-Ming Liao
Journal:  Front Pharmacol       Date:  2021-01-08       Impact factor: 5.810

8.  Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure.

Authors:  Ephraim B Winzer; Pauline Gaida; Robert Höllriegel; Tina Fischer; Axel Linke; Gerhard Schuler; Volker Adams; Sandra Erbs
Journal:  Cardiol Res Pract       Date:  2016-08-02       Impact factor: 1.866

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.